Pharvaris (NASDAQ:PHVS) Shares Up 10.3% - Should You Buy?

Key Points

• Pharvaris N.V. shares increased by 10.3%, reaching a last trading price of $23.29, despite a significant drop in trading volume.
• Investment analysts have varied ratings for Pharvaris, with an average price target of $37.17 and five analysts rating it as a Buy, while Weiss Ratings maintains a Sell rating.
• The company focuses on developing treatments for rare diseases, with ongoing clinical trials for its products targeting hereditary angioedema (HAE).

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s stock price rose 10.3% during mid-day trading on Monday . The company traded as high as $23.00 and last traded at $23.29. Approximately 48,919 shares traded hands during mid-day trading, a decline of 54% from the average daily volume of 106,158 shares. The stock had previously closed at $21.12.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Bank of America raised Pharvaris from an "underperform" rating to a "neutral" rating and raised their target price for the company from $16.00 to $27.00 in a report on Thursday, October 9th. JMP Securities decreased their target price on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a research report on Wednesday, August 13th. HC Wainwright started coverage on shares of Pharvaris in a report on Wednesday, October 15th. They issued a "buy" rating and a $60.00 target price for the company. Zacks Research upgraded shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $37.17.

Pharvaris Price Performance

The company has a fifty day moving average price of $23.03 and a two-hundred day moving average price of $19.42. The company has a market capitalization of $1.24 billion, a P/E ratio of -7.03 and a beta of -2.77.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). As a group, sell-side analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of PHVS. TFG Asset Management GP Ltd raised its position in Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock worth $3,311,000 after purchasing an additional 61,105 shares during the last quarter. TD Asset Management Inc raised its position in shares of Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company's stock worth $1,751,000 after acquiring an additional 21,388 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock worth $952,000 after acquiring an additional 15,769 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after acquiring an additional 7,879 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Pharvaris by 55.1% during the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock valued at $442,000 after purchasing an additional 10,006 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.